Introduction
============

Gastric cancer (GC) is the fourth-most-common cancer and the second leading cause of cancer-related deaths worldwide;[@b1-ott-8-567],[@b2-ott-8-567] in addition, nearly two-thirds of GCs occur in developing regions.[@b3-ott-8-567] As a multifactorial disease, both environmental factors and genetic factors contribute to the etiology of this disease.[@b4-ott-8-567],[@b5-ott-8-567] Although much treatment progress has been achieved in recent years, the prognosis of GC remains poor due to the delay in diagnosis.[@b6-ott-8-567] MicroRNAs (miRNAs) are RNA molecules with lengths of \~22 nucleotides; they can act as posttranscriptional regulators in mRNA expression, and they regulate a variety of physiological and developmental processes, including the development and progression of numerous cancers.[@b7-ott-8-567]--[@b13-ott-8-567] In GC, miRNAs can serve as biomarkers for both diagnosis and therapeutic targets.[@b14-ott-8-567]--[@b17-ott-8-567]

In miRNA processing, long primary transcripts of miRNAs (pre-miRNAs) are synthesized by RNase II in the nucleus, and they are cut into an \~70 nt hairpin precursor by RNase III Drosha and by the double-stranded RNA-binding protein DiGeorge syndrome critical region 8 (DGCR8). These precursors are exported to the cytoplasm, are processed by exportin-5 (*XPO5*) and RAN-GTPase (*RAN*), and are further diced into \~22 nt miRNA duplexes by the RNase III *Dicer* gene, which cooperates with the transactivation response RNA-binding protein and the Argonaute protein family. MiRNA duplexes are then assembled into the miRNA-induced silencing complex (miRISC), which contains *GEMIN3* and *GEMIN4*. The miRISC will select one strand as the mature miRNA, and it guides the mature miRNAs to their target mRNA sites.[@b18-ott-8-567]--[@b23-ott-8-567] MiRNA-related single nucleotide polymorphisms (miR-SNPs), which are defined as single-nucleotide polymorphisms (SNPs) in miRNA genes at the miRNA binding site and in miRNA processing machinery, can modulate miRNA and target gene expression to influence cancer development, promote therapeutic efficacy, and affect a patient's prognosis.[@b23-ott-8-567]--[@b26-ott-8-567] The miRNA machinery genes are linked to the development, progression, and prognosis of several cancer types, including ovarian and colorectal cancers, melanoma, and T-cell lymphoma.[@b27-ott-8-567]--[@b30-ott-8-567] However, the role of the miRNA processing machinery genes in GC remains uncertain.

In the present study, we genotyped six miR-SNPs in the miRNA processing machinery genes, including *XPO5* (rs11077), *RAN* (rs14035), *Dicer* (rs3742330), *TNRC6B* (rs9623117), *GEMIN3* (rs197412), and *GEMIN4* (rs2740348) in GC patients to evaluate the relationships of these genes with risk for development of GC.

Materials and methods
=====================

Sample collection and DNA extraction
------------------------------------

Blood samples were collected from GC patients who underwent GC resection at the Department of General Surgery at the Fourth Hospital of Hebei Medical University from 2007--2008. Blood samples were also collected from normal controls without a history of any cancer. Genomic DNA was immediately extracted using the Wizard^®^ Genomic DNA Purification Kit (Promega Corporation, Fitchburg, WI, USA) and was stored at −20°C. All procedures were supervised and approved by the Human Tissue Research Committee of the Fourth Hospital of Hebei Medical University. Written consent was obtained from all the patients and healthy controls enrolled in this study.

Genotyping of miR-SNPs
----------------------

The miR-SNPs of the miRNA processing gene, including *XPO5* (rs11077), *RAN* (rs14035), *Dicer* (rs3742330), *TNRC6B* (rs9623117), *GEMIN3* (rs197412), and *GEMIN4* (rs2740348), according to the National Center for Biotechnology Information (NCBI) SNP database (<http://www.ncbi.nlm.nih.gov/snp/>), were genotyped using the polymerase chain reaction (PCR)--ligase detection reaction assay with the primers and probes listed in [Table 1](#t1-ott-8-567){ref-type="table"}. PCR was performed with the PCR Master Mix Kit according to the manufacturer's instructions (Promega, Madison, WI, USA). Ligation was performed using the different probes that were matched to the miR-SNPs, and the ligated products were separated using the ABI PRISM Genetic Analyzer 3730XL (Applied Biosystems, Foster City, CA, USA) to access the length differences of the ligated products.

Statistical analysis
--------------------

The *χ*^2^ test was applied to analyze dichotomous variables, such as the presence or absence of an individual SNP in patients and healthy controls. The odds ratios and 95% confidence intervals (CI) were calculated using an unconditional logistic regression model. All of the statistical analyses were performed with the SPSS version 18.0 software package (IBM Corporation, Armonk, NY, USA). A *P*-value \<0.05 was considered statistically significant.

Results
=======

A total of 137 GC patients and 142 healthy controls were included in this study. The clinical characteristics of the cases and controls are listed in [Table 2](#t2-ott-8-567){ref-type="table"}. Six miR-SNPs were detected from the blood samples of the healthy controls and GC patients.

When individual SNPs were compared between GC patients and controls in terms of their distribution frequency, statistically significant increases for the C/C genotype of rs14035 in the *RAN* gene (95% CI: 1.601--14.925; *P*=0.002), the T/T genotype of rs9623117 in the *TNRC6B* gene (95% CI: 0.03--0.608; *P*=0.003), and the A/A genotype of rs3742330 in the *Dicer* gene (95% CI: 1.223--3.178; *P*=0.005) were observed in GC patients. These results indicate that the carriers of these alleles are susceptible to GC ([Table 3](#t3-ott-8-567){ref-type="table"}).

Discussion
==========

The miR-SNPs in *RAN*, *Dicer*, and *TNRC6B* were associated with the carcinogenesis of GC in our analysis. To our knowledge, this is the first report to indicate that the SNP sites in the miRNA processing machinery genes have predictive value for determining the incidence of GC.

*RAN* is a member of the Ras superfamily of GTPases and is essential for the translocation of pre-miRNAs from the nucleus to the cytoplasm. *XPO5* binds to pre-miRNA and RAN-GTPase in the nucleus (via the *XPO5*--*RAN* GTP--pre-miRNA heteroternary complex) to mediate the nuclear export of pre-miRNA in a *RAN* GTP-dependent manner.[@b31-ott-8-567] Disruption of pre-miRNA nucleocytoplasmic transport would impair the production of mature miRNAs in cancer cells. The fact that *RAN* is overexpressed in some cancer cell lines, including colon cancer, implies its role in tumor transformation; moreover, *RAN* was reported to suppress the activation of C-Jun-NH~2~-kinase and inhibit the apoptosis induced by an anticancer drug.[@b32-ott-8-567],[@b33-ott-8-567] The rs14035 located in *RAN* might alter *RAN* expression, so as to initiate carcinogenesis by modulating the production of mature miRNAs.

*Dicer* was also implicated in the oncogenic process of several cancers, but the data were controversial; downregulated *Dicer* expression has been identified in lung cancer, ovarian cancer, nasopharyngeal cancers, breast cancer, and esophageal cancer, whereas upregulated *Dicer* expression was found in lung adenocarcinoma, colorectal cancer, and primary cutaneous T-cell lymphomas.[@b27-ott-8-567],[@b34-ott-8-567]--[@b40-ott-8-567] The mechanism underlying how the rs3742330 SNP modified the GC risk remains unclear; the location of this SNP in the 3′-untranslated region of *Dicer* might potentially influence the stability and expression of the gene.

*TNRC6B* (or KIAA1093), localized on the mRNA-degrading cytoplasmic P bodies, is one of the three Argonaute-interacting protein paralogs in vertebrates. They assist in the formation of miRNA ribonucleoparticles or miRISCs, so as to mediate miRNA-guided mRNA cleavage.[@b16-ott-8-567],[@b41-ott-8-567]--[@b44-ott-8-567] The T/T genotype of rs9623117 in *TNRC6B* has been found to be associated with prostate cancer risk. Alterations in *TNRC6B* gene expression due to genetic variations of rs9623117 might perturb the levels of miRNA species normally under its control, thus contributing to carcinogenesis.[@b45-ott-8-567]

The frequency distribution of these six SNPs and the patients' clinical characteristics (including their sex, age, and tumor stage) do not appear to be associated, as determined by our analysis (data not shown). These six miR-SNPs were analyzed for their relationship with postoperative survival in 95 patients for whom 3-year follow-up data were available. It was found that rs2740348 showed a marginally statistically significant association with survival (*P*=0.06; our unpublished data). These findings should be validated with a larger sample size.

Although the results of this study require further validation among a larger GC cohort, as well as in laboratory-based functional studies, our data are encouraging because they demonstrate that miR-SNPs can be used to predict the risk for developing GC.
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###### 

All the primers and probes used for genotyping of miR-SNPs

  ------------------------------------------------------------------------------------------------------------------------
  Gene       rs NCBI                     Primer sequence                            Probe sequence
  ---------- --------------------------- ------------------------------------------ --------------------------------------
  *XPO5*     rs11077\                    F GAATCTGGTCACCTGATGGGA                    S1 GTACCTCCAAGGACCAGGGCTGGGA
             (A/C)                                                                  

             R GTGCCTGAGTGGACCTTGAG      S2 TTTGTACCTCCAAGGACCAGGGCTGGGC\           
                                         S3 AGTCTTTAGTGCTAACATCCCCTTT               

  *RAN*      rs14035\                    F GCACTTGCTCAAAATCTGTGA                    S1 TTTTAGTAATCATGTTTTAATGTAGAACC
             (C/T)                                                                  

             R TAACAGCAAGAATTCCCAACCCT   S2 TTTTTTTAGTAATCATGTTTTAATGTAGAA\         
                                         S3 TCAAACAGGATGGAACATCAGTGGATTT            

  *GEMIN4*   rs2740348\                  F TTGCCTCTGAGAAGAAGTGG                     S1 TTTTTTTTGGGAGTAACAGGGCCCTCTTCCGAC
             (G/C)                                                                  

             R GACTCAGGGATGGCTCTGTC      S2 TTTTTTTTTTGGGAGTAACAGGGCCCTCTTCCGAG\    
                                         S3 AGCCAGACTTGGTGTTGAGGCTGCTTTTTTT         

  *TNRC6B*   rs9623117\                  F TTTCT GTCTCCTCCTATCCAT                   S1 TCTCCCTGTTACTCTTAAGTAGTGC
             (C/T)                                                                  

             R CATTAGTTTAGCCAACAAGGT     S2 TTTTCTCCCTGTTACTCTTAAGTAGTGT\           
                                         S3 CTCCTTTCCCCATCCACCCCATCTC               

  *GEMIN3*   rs197412\                   F TAGAGAAACCTGTGGAAATCA                    S1 TTTTATGGTTTTGTGAGAAATAAAGTTAC
             (T/C)                                                                  

             R GAAGAGGTTCTTGAGCTGTAA     S2 TTTTTTTATGGTTTTGTGAGAAATAAAGTTAT\       
                                         S3 TGAACAGAGAGTCCCTGTGTTGGCATTT            

  *Dicer*    rs3742330\                  F AAAGGTATCAAGGTCTCAGTTTG                  S1 TTTTTTTTTTCAATCTTGTGTAAAGGGATTAGA
             (A/G)                                                                  

             R CTGCAGAGGATCACTGGAATC     S2 TTTTTTTTTTTTTCAATCTTGTGTAAAGGGATTAGG\   
                                         S3 CACCCTAACAGAGCAAGATCCAATATTTTTT         
  ------------------------------------------------------------------------------------------------------------------------

**Notes:** F: represents forward primer for PCR; R: represents reverse primer for PCR; S1 and S2 represent probes match to different allele of the SNP; S3 represents probes downstream of the SNP.

**Abbreviations:** NCBI, National Center for Biotechnology Information; PCR, polymerase chain reaction; SNP, single-nucleotide polymorphism.

###### 

Clinical characteristics in patients with gastric cancer and controls

  Characteristic               Case   Control   *P*-value
  ---------------------------- ------ --------- -----------
  Sex                                           0.959
   Male                        99     103       
   Female                      38     39        
  Age (years)                                   0.598
   ≤60                         68     66        
   \>60                        69     76        
  Clinical stage                                
   I + II                      47               
   III + IV                    90               
  Size of tumor(diameter)                       
   ≤5 cm                       73               
   \>5 cm                      64               
  Degree of differentiation                     
   Highly + moderately         88               
   Poorly + undifferentiated   49               
  Intravascular tumor emboli                    
   No                          100              
   Yes                         37               
  Tumor location                                
   Upper third                 49               
   Middle third                43               
   Lower third                 45               
  Lymph node metastasis                         
   N0                          42               
   N1                          31               
   N2                          31               
   N3                          33               
  Postoperative chemotherapy                    
   No                          64               
   Yes                         73               

###### 

miR-SNPs frequency difference between patients with gastric cancer and controls

  Variants    Gene       Genotype   Case   Control   *P*-value   OR      95% CI
  ----------- ---------- ---------- ------ --------- ----------- ------- ---------------
  rs11077     *XPO5*     A/A        119    123       0.953       1.021   0.511--2.040
  A/C + C/C   18         19                                              
  rs14035     *RAN*      C/C        86     35        0.002       4.888   1.601--14.925
  C/T + T/T   51         107                                             
  rs3742330   *Dicer*    A/A        75     54        0.005       1.971   1.223--3.178
  A/G + G/G   62         88                                              
  rs9623117   *TNRC6B*   T/T        135    128       0.003       0.135   0.03--0.608
  C/T + C/C   2          14                                              
  rs197412    *GEMIN3*   T/T        65     60        0.383       1.234   0.769--1.979
  C/T + C/C   72         82                                              
  rs2740348   *GEMIN4*   G/G        110    115       0.928       1.027   0.572--1.845
  C/G + C/C   27         29                                              

**Abbreviations:** CI, confidence interval; miR-SNP, microRNA-related single-nucleotide polymorphism; OR, odds ratio.
